Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
The 2016 World Health Organization classification of prostate cancer with neuroendocrine (NE) differentiation includes NE cells in usual prostate cancer, adenocarcinoma with Paneth cell-like NE differentiation, well-differentiated NE tumor (carcinoid), small cell NE carcinoma, and large cell NE carcinoma. In this article, we report a rare case of primary prostatic carcinoma with de novo diffuse NE differentiation presenting with bilateral hydronephrosis in a 79-year-old man. This case did not fit into any of the existing classifications. The clinical, radiological, morphological, and immunohistochemical findings and response to androgen deprivation therapy (ADT) are presented. The proposed pathogenesis of NE differentiation via transdifferentiation from conventional prostatic adenocarcinoma whereby genomic alterations, coupled with ADT can induce lineage plasticity resulting in NE differentiation is described.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9887995 | PMC |
| http://dx.doi.org/10.1177/10668969211035844 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Patient and Physician Perceptions of Prostate-Specific Antigen Testing Among Black Individuals.
JAMA Netw Open
September 2025
Department of Urology, Center for Health Outcomes Research and Dissemination, University of Washington, Seattle.
Importance: Black individuals have a twofold higher rate of prostate cancer death in the US compared with the average population with prostate cancer. Few guidelines support race-conscious screening practices among at-risk Black individuals.
Objective: To examine structural factors that facilitate or impede access to prostate cancer screening among Black individuals in the US.
Time to Prostate-Specific Antigen Failure as a Unique Prognosticator of Overall Survival in Biochemically Recurrent Prostate Cancer Patients Undergoing Radical Prostatectomy.
Adv Urol
August 2025
Department of Urology, Graduate School of Medicine, Yamaguchi University, Ube, Yamaguchi, Japan.
In biochemically recurrent prostate cancer (BRPC), no definitive independent prognostic factors were reported. This study aimed to identify the factors impacting overall survival (OS) in patients with BRPC after radical prostatectomy (RP). Among 610 consecutive patients who underwent RP between January 2000 and December 2019, with follow-up through December 2024, 152 (25%) patients who developed BRPC were analyzed.
View Article and Find Full Text PDFThe role of digital therapeutics in the management of prostate cancer: A systematic scoping review.
Digit Health
September 2025
Department of Nursing, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Background: Digital therapeutics (DTx) has emerged as a transformative approach in healthcare, offering innovative solutions for disease management and treatment optimization. Prostate cancer (PCa), the second most common malignancy in men, has seen increasing incidence rates, driving the development of new digital technologies for PCa management.
Purpose: This review aims to provide a comprehensive analysis of the current status and effectiveness of DTx in managing PCa.
The unexpected finding of breast and axillary metastases in a patient with prostate carcinoma.
Radiol Case Rep
November 2025
Department of Clinical and Experimental Medicine, Foggia University School of Medicine, Viale L. Pinto 1, 71122 Foggia, Italy.
We report a rare case of breast and axillary metastases in a 75-year-old man diagnosed with prostate carcinoma. Initially, the patient presented with lower urinary tract symptoms (LUTS) and elevated prostate-specific antigen (PSA) levels. Prostate cancer was confirmed by biopsy and treated with androgen deprivation therapy (ADT) and radiotherapy.
View Article and Find Full Text PDFCD63 is a diagnostic marker of prostate cancer and a prognostic marker of biochemical progression following radical prostatectomy.
Histol Histopathol
September 2025
Institute of Pathology, University Hospital Bonn, Bonn, Germany.
Aims: We aimed to analyze CD63, a cell surface protein that has been associated with tumor aggressiveness in several cancers, including breast, colorectal, and lung cancer, as well as melanoma, in prostate cancer.
Methods: CD63 expression was analyzed immunohistochemically in a cohort of primary prostate cancers from 281 patients. The results were correlated with clinico-pathologic parameters, including biochemical recurrence.